Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 162Carcinoma, Non-Small-Cell Lung 109Lung Neoplasms 54Hodgkin Disease 22Neoplasm Metastasis 16Recurrence 15Lymphoma 15Neoplasms 14Triple Negative Breast Neoplasms 13Prostatic Neoplasms 10Adenocarcinoma of Lung 10Sarcoma 9Rhabdomyosarcoma 9Uterine Cervical Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 6Ovarian Neoplasms 5Mesothelioma, Malignant 5Breast Neoplasms, Male 5Small Cell Lung Carcinoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4NSCLC 4Multiple Myeloma 4Brain Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

Vinorelbine 2Capecitabine 2ribociclib 1Trastuzumab 1Lapatinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × HER2-positive Advanced Breast Cancer × Vinorelbine × Clear all
NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
420 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT04903652 2022-04-07

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Completed
30 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡